Happy Holidays! This is the biggest gift we could possibly think of to give to our global community. Now SEMrush database contains more than 100 countries!
Check out the full list of countries we cover below. If you don’t find the country you wish we would have, please let us know. It will be added in no time. We're as agile as a SaaS company can be and over 50% of all our updates come from the wishes of our users.
Head over to the dashboard and unwrap your holiday gift. Happy holidays and huge hug from all the whole SEMrush family to yours.
Afghanistan
Albania
Angola
Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Belarus
Belize
Belgium
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Cabo Verde
Cambodia
Cameroon
Canada
Chile
Colombia
Costa Rica
Croatia
Cyprus
Czech Republic, the
Congo
Denmark
Dominican Republic, the
Ecuador
Egypt
El Salvador
Estonia
Ethiopia
Finland
France
Georgia
Germany
Ghana
Greece
Guatemala
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kuwait
Lebanon
Lithuania
Luxembourg
Libya
Madagascar
Malaysia
Malta
Mauritius
Mexico
Moldova
Mongolia
Montenegro
Morocco
Mozambique
Namibia
Nepal
New Zealand
Netherlands, the
Nicaragua
Nigeria
Norway
Oman
Paraguay
Peru
Philippines, the
Poland
Portugal
Romania
Russian Federation, the
Saudi Arabia
Senegal
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Thailand
Trinidad and Tobago
Tunisia
Turkey
Ukraine
United Arab Emirates, the
United Kingdom, the
United States of America, the
Uruguay
Venezuela
Vietnam
Zambia
As always, if you have any comments, suggestions or ideas, don’t hesitate to email us at
Today’s B2B content marketers live and die by data, and knowing what matters to their audiences can mean boom or bust. But with so much data to crunch, it’s harder than ever to cut through the noise and understand who they should target, how they should communicate and what kind of content to create.
Today, we’re excited to announce the launch of PYLON for LinkedIn Engagement Insights, a reporting API solution sold by DataSift, that lets marketers around the world access LinkedIn data to help them improve engagement with their content and deliver positive ROI on LinkedIn. Built in a way that respects member’s privacy, LinkedIn Engagement Insights helps...
at is why many men with an an early stage tumour choose to "wait and see" and have treatment only when it starts growing aggressively.
"This changes everything," said Prof Mark Emberton, who tried out the technique at University College London.
Triggered to kill
The new treatment uses a drug, made from bacteria that live in the almost total darkness of the seafloor and which become toxic only when exposed to light.
Ten fibre optic lasers are inserted through the perineum - the gap between the anus and the testes - and into the cancerous prostate gland.
When the red laser is switched on, it activates the drug to kill the cancer and leaves the healthy prostate behind.
The trial - at 47 hospitals across Europe - showed 49% of patients went into complete remission.
And during the follow-up, only 6% of patients needed to have the prostate removed, compared with 30% of patients that did not have the new therapy.
Crucially, the impact on sexual activity and urination lasted no more than three months.
No men had significant side effects after two years.
Gerald Capon, 68 and from West Sussex, told the BBC: "I'm totally cured and free of the cancer.
"I feel incredibly lucky that I was accepted for the trial... I feel that my life ahead is worry free."
He was out of hospital the day after the treatment.
Image captionPatient Gerald Capon says he feels incredibly lucky
Prof Emberton said the technology could be as significant for men as the move from removing the whole breast to just the lump in women with breast cancer.
He said: "Traditionally the decision to have treatment has always been a balance of benefits and harms.
"The harms have always been the side effects - urinary incontinence and sexual difficulties in the majority of men.
"To have a new treatment now that we can administer, to men who are eligible, that is virtually free of those side effects, is truly transformative."
More than 46,000 men are diagnosed with prostate cancer in the UK each year.
The tumours tend to grow slowly, but still around 11,000 men die from the disease.
However, the new treatment is not yet available for patients. It will be assessed by regulators at the beginning of next year.
Other therapies to kill prostate cancers, such as very focused ultrasound - known as focal Hifu - have a lower risk of side effects.
But these treatments are not universally available.
Dr Matthew Hobbs, from the charity Prostate Cancer UK, said the technology could help men who face the conundrum of whether or not to have treatment.
"Focal therapy treatments like this one have the potential to offer a middle ground option for some men with cancer that has not spread outside the prostate," he said.
Caution urged
He said the next challenge would be to find out which patients should still wait and see, which ones should have this type of therapy, and which should have more invasive treatments.
"Until we know the answer to this question, it is important that these results do not lead to the over-treatment of men with low risk cancer, or the under treatment of men at higher risk."
The technology was developed at the Weizmann Institute of Science in Israel alongside Steba Biotech.